{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.8","upperLimit":"57.1","value":"45.8"},{"groupId":"OG001","lowerLimit":"26.8","upperLimit":"50.3","value":"38.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"PSA response is defined as a ≥ 50% decline in PSA from baseline with PSA confirmation ≥ 3 weeks after the first documented reduction in PSA of ≥ 50%.","dispersionType":"95% Confidence Interval","groups":[{"description":"vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks","id":"OG000","title":"Part 1: MGC018 2.0 mg (Arm A)"},{"description":"vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks","id":"OG001","title":"Part 1: MGC018 2.7 mg (Arm B)"},{"description":"abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.","id":"OG002","title":"Part 1: Control Arm"},{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG003","title":"Part 2"}],"paramType":"NUMBER","populationDescription":"All participants in Part 1 who received at least one dose of study treatment, with a baseline PSA ≥ 2 ng/mL and at least one post-baseline PSA measurement (PSA Response Evaluable Population). There were no participants in the Control Arm that were part of the PSA Response Evaluable Population.\n\nParticipants in Part 2 did not have mCRPC, so were not assessed using PSA measurement.","reportingStatus":"POSTED","timeFrame":"Every 4 weeks throughout study participation. Average duration 10 months.","title":"Part 1: Prostate-specific Cancer Antigen (PSA) Response Rate Per PCWG3 Criteria","type":"SECONDARY","unitOfMeasure":"percent"}